相关实验视频

Updated: Jun 5, 2025

Novel Percutaneous Approach for Deployment of 3D Printed Coronary Stenosis Implants in Swine Models of Ischemic Heart Disease

Novel Percutaneous Approach for Deployment of 3D Printed Coronary Stenosis Implants in Swine Models of Ischemic Heart Disease

Published on: February 18, 2020

药物涂层气球在复杂高风险和指示皮肤冠状动脉干预中的应用

Yvemarie B O Somsen¹, Tuomas T Rissanen², Roel Hoek¹

¹Department of Cardiology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions

|December 11, 2024

概括

药物涂层气球 (DCB) 为接受复杂高风险指示皮肤冠状动脉干预 (CHIP) 的患者提供了一种有希望的替代药物排泄支架 (DES). DCBs可以减少支架负担,并简化复杂冠状动脉病变的程序.

科学领域:

干预心脏病学干预心脏病学
心血管医学心血管医学
医疗器械技术医疗器械技术

背景情况:

患有重大并发症的患者接受皮肤冠状动脉干预 (PCI) 的患病率越来越高.
复杂高风险指示PCI (CHIP) 涉及多种并发症和复杂冠状动脉解剖的患者.
药物排泄支架 (DES) 可能导致CHIP患者的支架负担增加.

研究的目的:

审查有关在CHIP患者中使用药物涂层气球 (DCB) 的现有证据.
在复杂的PCI场景中评估DCB作为DES的替代品或辅助.
评估DCB在减少支架负担和简化CHIP中的PCI方面的潜在好处.

主要方法:

对观察性研究和有关CHIP患者使用DCB的现有数据的审查.
分析DCB策略,包括混合 (DCB和DES) 和仅使用DCB的方法.
在特定的CHIP患者子组和病变类型中评估DCB应用.

主要成果:

观察数据表明,在CHIP患者中使用DCB的门较低,特别是具有多种风险因素的患者.
DCBs可以减少在分叉病变和慢性全闭症中需要广泛的DES植入的需要.
在患有出血风险的患者中,DCBs可能有助于缩短双抗血小板治疗的持续时间.

结论:

药物涂层气球 (DCB) 对CHIP患者来说是一个可行的治疗选择.
在特定的CHIP病例中,DCB可以作为DES的补充或作为独立疗法.
需要进一步的随机试验来确认DCB在CHIP患者的益处,特别是关于抗血小板治疗的持续时间.

关键词:

晚期冠状动脉疾病是冠状动脉疾病.这是一个复杂的高风险PCI.用药物涂层的气球.通过皮肤进行冠状动脉干预.

更多相关视频

A Rat Carotid Artery Pressure-Controlled Segmental Balloon Injury with Periadventitial Therapeutic Application

A Rat Carotid Artery Pressure-Controlled Segmental Balloon Injury with Periadventitial Therapeutic Application

Published on: July 9, 2020

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

相关概念视频

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...